George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
i think its about getting the first order through, and thereafter we can build on that.
I've been thinking a lot about this, and it seems that this is the wrong time to do mass antibody testing. Allow me to explain.
This is a moment of lockdown, not releasing restrictions. imagine giving a license to some to live normal lives right now....Once the government has a grip on daily cases, daily hospitalisations, daily deaths, they may well consider easing some restrictions and that's where antibody tests play an important part. Same way we have regional lockdowns, perhaps they would have regional releases...??
Come Feb / March 2021, possibly after wave 2, they'll need to do a lot of antibody testing to gauge what % of the population have antibodies.
Likewise, when the vaccine comes, they'll need to do a lot of testing then too about who is eligible and who isn't.
However for the consortium, this isn't kicking the can down the road, given that we can only make 200k tests a month in October, I think to produce a few million tests is definitely more than a few weeks work. The government dont like to mess around and hence dealing with small companies doesnt work well with them. Imagine signing an agreement only to be told they can have a few hundred thousand tests a week.
They want big numbers, and quite frankly we are not ready to give them big numbers....yet
Thanks for comments MB.
Hope am right , would be a true and fair consortium then , assuming they have shared the R&D costs it should be really .
Feel the £1.50 is a bit light considering the amount of money that has been invested to produce the gold standard triple antibody test
£13 per a test including posting / packaging to the public’s home looks about right to me, as per Abingdons white paper release last week.
Sure we will find out soon, as you say.
Okehurst - At the moment I am working on the basis that we are a supplier to the UK RTC at £1.50 a unit for UK Gov sales. Clearly for non gov sales we should expect a higher return. But the set up of the UK RTC is one thing that perhaps needs to be ironed out. Because Abingdon are the lead. In who's name will sales be registered? Do they set up a formal JV? Do the 4 companies look after their own private sales after UK Gov? If the total interest and expected sales is far greater than the government commitment, they may just agree a flat price for all units, say £2, knowing that if they lose on UK gov sales they gain elsewhere. We will just have to wait on the details, and I am sure we will learn more before the MOU expires, but the base assumption of 200k per week @ £1.50 will be highly lucrative, with 800k spare for higher profit Mologic tests. Anything more fruitful than that will be a bonus.
MB , fully agree.
What’s your take on our revenue from the test and how it’s distributed ?
If all partners of the RTC are equal and let’s assume they are then as such there must be a’ fair share ‘ policy for each member as it’s probably the only way they could agree terms, ie if it’s 30M p/m from the Government it’s 7.5M tests each to supply.
So a profit as such won’t be the mechanism to distribute the revenue it will be being the gross revenue to each member for each of their tests , less maybe distribution / marketing costs if this is being handled by CIBA
Each member of the consortium will have their own individual cost of doing business expenses including cost of capital, standard business stuff, that’s their affair.
My take is we will receive the same price as other partners and as I say less a distribution / administration cost
Could be £13 a test less a small charge per test that’s it.
Obviously it matters because Covid 19 stocks appear to be getting valued up to 2 times revenue, on 8M tests a month which is feasible then ODX will be generating over £100M a month gross, assuming they sell all at £13? And why wouldn’t they it’s the best anti body test on the market and there has been a lot of capital outlayed.
What’s your opinion ?
Agree MB
Yes it is a good long term play, but i believe any day there will be a huge RNS that will blow the market away.
"Have to hand it to you long term holders here you sure have some patience waiting for the golden RNS on what seems an ever extending timeline.
Hope the rise is as good as you are hoping you’ve certainly earned it."
That's just it.... there isn't going to be some "golden RNS" - that's not what ODX about.
This isn't a share for the 10%ers - this is a share for long term investors who understand the breadth of the ODX offering.
Have to hand it to you long term holders here you sure have some patience waiting for the golden RNS on what seems an ever extending timeline.
Hope the rise is as good as you are hoping you’ve certainly earned it.